Literature DB >> 20497510

A large number of mature and functional dendritic cells can be efficiently generated from umbilical cord blood-derived mononuclear cells by a simple two-step culture method.

Sreekumar Balan1, Vaijayanti P Kale, Lalita S Limaye.   

Abstract

BACKGROUND: Advances in the past two decades in dendritic cell (DC) biology paved the way to exploit them as a promising tool in cancer immunotherapy. The prerequisite for DC vaccine preparations is large-scale in vitro generations of homogeneous, mature, and functional DCs. Frequent improvements are being made in the existing in vitro DC production protocols to achieve this goal. In our previous study we reported a large-scale generation of mature, functional DCs from umbilical cord blood (UCB) CD34+ cells. Here we report that this method can be used for the efficient generation of DCs from UCB mononuclear cells (MNCs) and thus the hematopoietic stem cell isolation step is not essential. STUDY DESIGN AND METHODS: MNCs or CD34+ cells isolated from the same cord blood (CB) samples were used for the generation of DCs. DCs were characterized for morphology, phenotype, and functional assays including antigen uptake, chemotaxis, and mixed leukocyte reaction. Similarly DCs generated from the MNCs of same fresh and frozen CB units were compared.
RESULTS: The morphologic, phenotypic, and functional characterization of the DCs generated from various sets show that they were comparable in nature irrespective of the starting population used.
CONCLUSION: We conclude that the CD34+ isolation step is not essential for the generation of mature, functional DCs and thus can be eliminated. More importantly, we show that DCs can be generated with equal efficiency from the MNCs of frozen CB units. Our culture method will be useful for exploiting the potential of UCB as an additional source for allogeneic DCs in the clinical settings.
© 2010 American Association of Blood Banks.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20497510     DOI: 10.1111/j.1537-2995.2010.02706.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  7 in total

1.  Differentiated Cells Derived from Hematopoietic Stem Cells and Their Applications in Translational Medicine.

Authors:  Sophia S Fernandes; Lalita S Limaye; Vaijayanti P Kale
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Dendritic cells the tumor microenvironment and the challenges for an effective antitumor vaccination.

Authors:  Fabian Benencia; Leslee Sprague; John McGinty; Michelle Pate; Maria Muccioli
Journal:  J Biomed Biotechnol       Date:  2012-03-15

3.  Placenta-derived mesenchymal stem cells possess better immunoregulatory properties compared to their cord-derived counterparts-a paired sample study.

Authors:  Manasi D Talwadekar; Vaijayanti P Kale; Lalita S Limaye
Journal:  Sci Rep       Date:  2015-10-28       Impact factor: 4.379

4.  Exogenous addition of arachidonic acid to the culture media enhances the functionality of dendritic cells for their possible use in cancer immunotherapy.

Authors:  Jeetendra Kumar; Rupali Gurav; Vaijayanti Kale; Lalita Limaye
Journal:  PLoS One       Date:  2014-11-04       Impact factor: 3.240

5.  Autologous Hematopoietic Stem Cells Are a Preferred Source to Generate Dendritic Cells for Immunotherapy in Multiple Myeloma Patients.

Authors:  Prajakta Shinde; Sameer Melinkeri; Manas Kumar Santra; Vaijayanti Kale; Lalita Limaye
Journal:  Front Immunol       Date:  2019-05-21       Impact factor: 7.561

6.  Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells.

Authors:  Sreekumar Balan; Vincent Ollion; Nicholas Colletti; Rabie Chelbi; Frédéric Montanana-Sanchis; Hong Liu; Thien-Phong Vu Manh; Cindy Sanchez; Juliette Savoret; Ivan Perrot; Anne-Claire Doffin; Even Fossum; Didier Bechlian; Christian Chabannon; Bjarne Bogen; Carine Asselin-Paturel; Michael Shaw; Timothy Soos; Christophe Caux; Jenny Valladeau-Guilemond; Marc Dalod
Journal:  J Immunol       Date:  2014-07-09       Impact factor: 5.422

7.  Umbilical cord blood-derived CD11c(+) dendritic cells could serve as an alternative allogeneic source of dendritic cells for cancer immunotherapy.

Authors:  Jeetendra Kumar; Vaijayanti Kale; Lalita Limaye
Journal:  Stem Cell Res Ther       Date:  2015-09-25       Impact factor: 6.832

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.